CAMBRIDGE, Mass. and BEIJING, China, Aug. 30, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the following upcoming investor conferences:

Baird’s 2017 Global Healthcare Conference
Date: Wednesday, September 6, 2017
Time: 12:15 PM ET
Location: New York, NY

Morgan Stanley 15^th Annual Global Healthcare Conference
Date: Tuesday, September 12, 2017
Time: 3:30 PM ET
Location: New York, NY

Live webcasts of the presentations can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. Archived replays will be available for 90 days following the event.

About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.

Investor/Media Contact

Lucy Li, Ph.D.
+1 781-801-1800
ir@beigene.com 
media@beigene.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.